Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

Ida Hude, Anja Tea Golubić, Sandra Bašić-Kinda, Antonela Lelas, Ida Ivek, Helena Markotić, Martina Morić Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, Margareta Dobrenić, Snježana Dotlić, Ivana Ilić, Dražen Huić, Igor Aurer

Blood (2024) 144 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2024-209649

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Incidence of Secondary Primary Malignancies after Long-Term Follow up of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation - Report from Croatian Cooperative Group for Hematologic Malignancies (KroHem)

Blood (2023) 142 (Supplement 1): 6693.

https://doi.org/10.1182/blood-2023-186783

Published: 2023

Journal Articles

Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL), Unclassifiable B-Cell Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - a Real-Life Multicenter Study By the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Ida Hude, Klara Brčić, Martina Morić Perić, Vibor Milunović, Milan Vujčić, Ivan Krecak, Zdravko Mitrović, Božena Coha, Slavko Gašparov, Snježana Dotlić, Ivana Ilić, Sandra Bašić-Kinda, Igor Aurer, Goran Rinčić

Blood (2023) 142 (Supplement 1): 7394.

https://doi.org/10.1182/blood-2023-187158

Published: 2023

Journal Articles

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Sandra Basic - Kinda, Roman Hajek, Ankit Pahwa, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy A. Ross, Carlos Hader

Blood (2022) 140 (Supplement 1): 12481–12482.

https://doi.org/10.1182/blood-2022-159677

Published: 2022

Journal Articles

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study

Zrinka Sertić, Marko Lucijanic, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Bozena Coha, Drazen Pulanic, Dragana Šegulja, Dunja Rogić, Toni Valkovic, Igor Aurer, Nadira Durakovic

Blood (2021) 138 (Supplement 1): 47.

https://doi.org/10.1182/blood-2021-153573

Published: 2021

Journal Articles

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases

Igor Aurer, Ozren Jaksic, Sandra Bašić-Kinda, Stefan Mrdenovic, Slobodanka Ostojic Kolonic, Dominik Lozic, Hrvoje Holik, Sabina Novakovic Coha, Petra Bernes, Ivan Krecak, Martina Moric Peric, Marino Narancic, Zdravko Mitrovic, Toni Valkovic

Blood (2021) 138 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2021-149613

Published: 2021

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Extracellular Circulating DNA in Lymphoma Patients: Biological Correlates and Prognostic Impact

Dino Dujmovic, MD, Vedrana Skaro, Sandra Basic-Kinda, MD, Dora Markulin, Ivana Samarzija, Pavle Roncevic, MD, Ivo Radman, MD, Danijela Kolenc, MD PhD, Klara Dubravcic, Gordan Lauc, Igor Aurer, MD PhD

Blood (2014) 124 (21): 5365.

https://doi.org/10.1182/blood.V124.21.5365.5365

Published: 2014

Journal Articles

Clinical Utility of Heavy/Light Chain Assay for Evaluation and Prognostication in Multiple Myeloma Patients

Josip Batinic, MD, Zinaida Peric, MD, Dragana Segulja, James Last, Sanja Perkovic, Klara Dubravcic, Lidija Volaric, Dubravka Sertic, MD, Ivo Radman, MD, Sandra Basic-Kinda, MD, Danica Matisic, PhD, Drago Batinic, MD PhD, Boris Labar, MD PhD, Damir Nemet, MD PhD

Blood (2014) 124 (21): 2050.

https://doi.org/10.1182/blood.V124.21.2050.2050

Published: 2014

Journal Articles

Dose-Intense BACOP for Treatment of High Risk Peripheral T-Cell NHL (PTCL)

Igor Aurer, MD, PhD, Dino Dujmovic, MD, Ivo Radman, MD, Sandra Basic-Kinda, MD, Damir Nemet, MD, PhD, Ivana Ilic, MD, PhD, Ranka Stern-Padovan, MD, PhD, Fedor Santek, MD, PhD, Dubravka Sertic, MD

Blood (2010) 116 (21): 4889.

https://doi.org/10.1182/blood.V116.21.4889.4889

Published: 2010

Journal Articles

Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience.

Sandra Basic-Kinda, Igor Aurer, Dino Dujmovic, Ivo Radman, Dubravka Sertic, Klara Dubravcic, Koraljka Gjadrov-Kuvezdic, Drago Batinic, Mirna Sucic, Boris Labar

Blood (2009) 114 (22): 2372.

https://doi.org/10.1182/blood.V114.22.2372.2372

Published: 2009

NARROW

Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Incidence of Secondary Primary Malignancies after Long-Term Follow up of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation - Report from Croatian Cooperative Group for Hematologic Malignancies (KroHem)

Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL), Unclassifiable B-Cell Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - a Real-Life Multicenter Study By the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Extracellular Circulating DNA in Lymphoma Patients: Biological Correlates and Prognostic Impact

Clinical Utility of Heavy/Light Chain Assay for Evaluation and Prognostication in Multiple Myeloma Patients

Dose-Intense BACOP for Treatment of High Risk Peripheral T-Cell NHL (PTCL)

Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only